Gsk Share Discussion Threads

[abdullla] 14/9/2023 19:31

TM but you are indeed,like the rest of us,are sitting on heavy paper losses.

[patientcapital] 14/9/2023 14:20

VOD seems to have found its feet lately.

[1trustnobody] 14/9/2023 14:20

Upside remains as long as 1422 is support

[pierre oreilly] 14/9/2023 13:34

'about' = anhar

[pierre oreilly] 14/9/2023 13:34

Just wondering about, do you have any other debt guzzling Divi slashers you could recommend? This one's doing quite well, you must be coining it in. Wouldn't mind another like this.

[tradermichael] 14/9/2023 09:58

FYI, the lowest price I have paid (for shares that I currently hold) is: 1398.52, and the highest is: 1774.95. However I have bought and (sold) at various prices over the years, and currently own many 'tranches' at prices in between .... ;o)

[alibizzle] 13/9/2023 21:12

Same as tradermicheal

[abdullla] 13/9/2023 20:24

What were your highest and the lowest share prices,old man!

[alibizzle] 13/9/2023 18:13

I've held GSK shares for 27 years .

[anhar] 13/9/2023 11:29

I may well be a loon, but one who has been investing for decades in my long term income port strategy that has worked well for me, both in its aim of delivering a rising divi income and, although that's not why I do it, done quite well on capital too, assisted by reinvesting surplus income and corporate actions like bids, demergers etc.

As for GSK "steadily rising in price", well that depends on the time you are considering. Yours appears to be about five minutes, mine is forever in my port.

[pierre oreilly] 13/9/2023 09:50

Spot on anhar, I'm 'smarting' no end from something or other Are you 'smarting' from being born a loon who holds lots of shares in a company he thinks is a debt guzzler and a Divi slasher and doesn't have a good word to say about them, even while it's steadily rising in price?

[tradermichael] 13/9/2023 09:27

- and 25 years since it gave up 2088p

[alibizzle] 13/9/2023 09:24

Well it's been 14 months of waiting since the share price collapse

[rikky72] 12/9/2023 16:27

If you change your outlook to months rather than microseconds you may (eventually) be pleasantly surprised..

[panache1] 12/9/2023 15:32

What a shame !

[abdullla] 12/9/2023 14:41

But its decided to do otherwise

[alibizzle] 12/9/2023 11:14

Just get to £17 and i will sell

[anhar] 12/9/2023 10:44

PoR:We know your views anhar, debt guzzler, Divi slasher. That's all you've said in your last five posts. Oh, you also added you still hold a lot. Stranger and stranger. I'd sell if I thought like you...

Still smarting over your recent inaccurate claim that GSK/HLN is not a divi slasher?

I've also said that I'm a very long term income investor with a widely diversified port and rarely sell any share. It has to go seriously wrong, typically suspending divis with little hope of recovery, before I'll look at selling. GSK/HLN is nowhere near that bad but the fact is that it has been one of my poorer holds, and I've been in it for decades.

The two reasons I've mentioned several times may well be something to do with that.

[lippy4] 11/9/2023 20:55

? time will tell..

[tradermichael] 11/9/2023 19:41

Yes, but is it enough to cause this level of price rise?


GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator
● Regulatory submission included data from pivotal trials addressing key clinical manifestationsof myelofibrosis, namely splenomegaly,constitutional symptoms and anaemia
GSK plc (LSE/NYSE: GSK) today announced that the Ministry of Health, Labour and Welfare (MHLW), Japan, has accepted for review a new drug application (NDA) for momelotinib, a potential new medicine with a differentiated mechanism of action that may address the significant medical needs of myelofibrosis patients, especially those with anaemia.The NDA is based on data from the pivotal phase III trials SIMPLIFY-1 and MOMENTUM.

[chippyfriday] 11/9/2023 15:56

This from ADVFN might be the reason for the rise:

GSK rose as it announced that Japanese regulators are reviewing its proposed new momelotnib treatment for people with myelofibrosis - a type of blood cancer.

[pierre oreilly] 11/9/2023 14:53

We know your views anhar, debt guzzler, Divi slasher. That's all you've said in your last five posts. Oh, you also added you still hold a lot. Stranger and stranger. I'd sell if I thought like you.But ATM, I'm very happy while it's rising, probably due to shingles jingles.

[anhar] 11/9/2023 10:41

Shingles jingles, GSK needs to find a cure for its two serious ailments, divi slashing and debt guzzling.

[tradermichael] 11/9/2023 09:53

At 70 years and over, Shingrix will provide 89% protection, while Zostavax offers 41%. The Zostavax vaccine contains a live virus, which makes it unsafe for people with weakened immunity. On the other hand, Shingrix is safe for everyone, including 18-year-olds with compromised immunity.

Zostavax has been taken off the US market. Also, Shingrix is now the standard vaccine used within the UK as it may provide higher levels of protection that last longer.

As more markets are taking up Shingrix (e.g. China) this will provide a massive boost to GSK.

[pierre oreilly] 11/9/2023 09:18

Saw a FB ad by gsk informing everyone about shingles, so it looks like gsk jabs may be given on that market. (UK lowering age for shingles jab). Millions of extra jabs there every year.